[go: up one dir, main page]

PE20060010A1 - 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C - Google Patents

2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C

Info

Publication number
PE20060010A1
PE20060010A1 PE2005000219A PE2005000219A PE20060010A1 PE 20060010 A1 PE20060010 A1 PE 20060010A1 PE 2005000219 A PE2005000219 A PE 2005000219A PE 2005000219 A PE2005000219 A PE 2005000219A PE 20060010 A1 PE20060010 A1 PE 20060010A1
Authority
PE
Peru
Prior art keywords
diazepine
chloro
benzo
tetrahydro
ethyl
Prior art date
Application number
PE2005000219A
Other languages
English (en)
Inventor
John Gordon Allen
Karin Briner
Christopher Stanley Galka
Maria Angeles Martinez-Grau
Michael John Rodriguez
Andrew Caerwyn Williams
Steven Armen Boyd
Ajay Singh
Christopher Stephen Siedem
Wai-Man Lee
Arundhati S Deo
Richard Gerard Conway
Deyi Zhang
Frantz Victor
Roger Ryan Rothhaar
Matthew Robert Reinhard
Sarah Lynne Hellman
Michael Philip Cohen
Michael Wade Tidwell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20060010A1 publication Critical patent/PE20060010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS, DE FORMULA (I), EN DONDE R1 ES H, F, O ALQUILO(C1-C3); CADA R2, R3, Y R4 SON INDEPENDIENTEMENTE H, METILO O ETILO; R5 ES H, F, METILO, O ETILO; R6 ES -C*C-R10, -O-R12, -S-R14, O -NR24R25; R7 ES H, HALO, CIANO, ENTRE OTROS; R8 ES H, HALO, CIANO, O -SCF3; R9 ES R8, -CF3 O ALCOXI OPCIONALMENTE SUSTITUIDO; R10 ES -CF3, ETILO SUSTITUIDO, Ar1-ALQUILO(C0-C3), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE 6-(3-FENIL-PROP-1-INIL-2,3,4,5-TETRAHIDROBENZO[d]DIAZEPINA, 7-CLORO-5-{2-[(PIRIDINA-2-CARBONIL)AMINO]-ETOXI}-2,3,4,5-TETRAHIDROBENZO[d]DIAZEPINA, 7-CLORO-6-[2-(2,2-DIMETILPROPIONILOXI)-ETILTIO]-2,3,4,5-TETRAHIDROBENZO[d]DIAZEPINA, 7-CLORO-6-{4-[1-(1,1,2,2-PENTAFLUOROETIL)-ETOXI]-PIRIDIN-2-ILMETILAMINO}-2,3,4,5-TETRAHIDROBENZO[d]DIAZEPINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR DE SEROTONINA 5-HT2C, POR LO QUE SON UTILES EN EL TRATAMIENTO DE OBESIDAD, HIPERFAGIA, TRANSTORNO OBSESIVO/COMPULSIVO, DEPRESION O ANSIEDAD
PE2005000219A 2004-02-25 2005-02-24 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C PE20060010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54768104P 2004-02-25 2004-02-25

Publications (1)

Publication Number Publication Date
PE20060010A1 true PE20060010A1 (es) 2006-02-11

Family

ID=34910927

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000219A PE20060010A1 (es) 2004-02-25 2005-02-24 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C

Country Status (29)

Country Link
US (2) US8022062B2 (es)
EP (2) EP1720836B1 (es)
JP (1) JP4796047B2 (es)
KR (1) KR100848411B1 (es)
CN (3) CN1934088A (es)
AR (1) AR048242A1 (es)
AU (1) AU2005217602B2 (es)
BR (1) BRPI0507986A (es)
CA (1) CA2556390C (es)
CL (1) CL2010001292A1 (es)
CR (1) CR8566A (es)
DK (1) DK1720836T3 (es)
DO (1) DOP2005000024A (es)
EA (1) EA011011B1 (es)
EC (1) ECSP066788A (es)
ES (2) ES2466641T3 (es)
IL (1) IL177267A (es)
MA (1) MA28486B1 (es)
MY (1) MY141992A (es)
NO (1) NO20064277L (es)
NZ (2) NZ586553A (es)
PE (1) PE20060010A1 (es)
PL (1) PL1720836T3 (es)
PT (1) PT1720836E (es)
SI (1) SI1720836T1 (es)
SV (1) SV2005002025A (es)
UA (1) UA85699C2 (es)
WO (1) WO2005082859A1 (es)
ZA (1) ZA200606580B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
BRPI0615048A2 (pt) * 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
PT1924560E (pt) * 2005-09-01 2009-10-23 Lilly Co Eli 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c
US7981882B2 (en) 2005-09-01 2011-07-19 Eli Lilly And Company 6-N-linked heterocycle-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
ES2328408T3 (es) * 2005-09-01 2009-11-12 Eli Lilly And Company 2,3,4,5-tetrahidro-1h-benzo(d)azepinas 6-sustituidas como agonistas del receptor 5-ht2c.
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
EP2288585A1 (en) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-ht2c agonist (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CN101712675B (zh) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
MX2011005801A (es) * 2008-12-01 2011-06-20 Procter & Gamble Sistemas de perfume.
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
EP2504316A1 (en) 2009-11-23 2012-10-03 MSD Oss B.V. Heterocylic compounds as antagonists of the orexin receptors
US20110269744A1 (en) 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
EP2611782A1 (en) 2010-09-01 2013-07-10 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
JP2013536858A (ja) * 2010-09-01 2013-09-26 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストの速く溶解する剤形
CN103347523A (zh) 2010-09-01 2013-10-09 艾尼纳制药公司 向具有肾损伤的个体给药氯卡色林
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
CN103189053A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 用于体重控制的5-ht2c激动剂的调节释放剂型
WO2012046869A1 (ja) 2010-10-08 2012-04-12 持田製薬株式会社 環状アミド誘導体
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
CN103030604A (zh) * 2011-10-10 2013-04-10 上海医药工业研究院 4-烷基-5-甲酰基噻唑或5-甲酰基噻唑的制备方法
CN103145619A (zh) * 2012-06-15 2013-06-12 史慎德 7-氯-6-苯磺酰氨基-2,3,4,5-四氢-1H-苯并[d]氮杂*的制备
CA2886875A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2801575A1 (en) 2013-05-07 2014-11-12 Bayer CropScience AG Heteroaryldihydropyridine derivatives as fungicides
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN103864679B (zh) * 2014-03-21 2015-11-18 河南师范大学 一种3-甲基-2-吡啶甲酸甲酯的制备方法
CN104193656B (zh) * 2014-09-09 2016-01-06 太原理工大学 一种β-二羰基砜类化合物及其制备方法
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
JP2018514572A (ja) 2015-04-30 2018-06-07 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント オキシンドール化合物およびその医薬組成物
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド レベチラセタムの持続放出性医薬組成物
JP7160487B2 (ja) 2017-05-04 2022-10-25 ビーエーエスエフ ソシエタス・ヨーロピア 植物病原菌を駆除するための置換５－（ハロアルキル）－５－ヒドロキシ－イソオキサゾール
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
KR20210124292A (ko) 2019-02-01 2021-10-14 에프엠씨 코포레이션 제초제로서 디아미노-치환된 피리딘 및 피리미딘
WO2020239855A1 (en) 2019-05-29 2020-12-03 Syngenta Crop Protection Ag Microbiocidal derivatives
US20230322715A1 (en) * 2019-10-14 2023-10-12 The Regents Of The University Of California Broad spectrum anti-cancer compounds
CN115667236B (zh) * 2020-04-26 2024-04-26 江苏恩华药业股份有限公司 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2265890A (en) * 1939-11-25 1941-12-09 Arrow Hart & Hegeman Electric Combined face plate and receptacle
US4265890A (en) * 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA792785B (en) * 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) * 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
WO1995009159A1 (en) 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
US5698766A (en) 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
AU4797400A (en) 1999-05-17 2000-12-05 Eli Lilly And Company Metabotropic glutamate receptor antagonists
WO2001007416A1 (de) 1999-07-28 2001-02-01 Lonza Ag Verfahren zur herstellung von pyridazincarbonsäurederivaten
BR0014447A (pt) 1999-09-29 2002-06-11 Lilly Co Eli Derivados de piperidina como inibidores da reabsorção
GB0005789D0 (en) 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
EP1213017A3 (en) 2000-12-05 2003-11-12 Akzo Nobel N.V. Use of a 5-HT2C receptor agonist for the treatment of hot flushes
WO2002074746A1 (en) 2001-03-16 2002-09-26 Yamanouchi Pharmaceutical Co., Ltd. Benzazepine derivatives
JP2005522408A (ja) 2001-07-13 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ＨＴ受容体リガントとしてのヘキサヒドロアゼピノ（４，５−ｇ）インドールおよびインドリン
MXPA04005151A (es) 2001-11-28 2004-08-11 Upjohn Co Compuestos terapeuticos.
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators

Also Published As

Publication number Publication date
US8022062B2 (en) 2011-09-20
EP1720836A1 (en) 2006-11-15
BRPI0507986A (pt) 2007-07-24
NZ586553A (en) 2011-11-25
US20120028961A1 (en) 2012-02-02
PT1720836E (pt) 2014-07-16
JP2007523951A (ja) 2007-08-23
PL1720836T3 (pl) 2014-09-30
ES2468741T3 (es) 2014-06-16
IL177267A (en) 2011-10-31
CN1934088A (zh) 2007-03-21
CL2010001292A1 (es) 2011-07-15
EP2479168B1 (en) 2014-04-09
CN102311387A (zh) 2012-01-11
MA28486B1 (fr) 2007-03-01
EP1720836B1 (en) 2014-04-16
KR100848411B1 (ko) 2008-07-28
CA2556390A1 (en) 2005-09-09
KR20070001200A (ko) 2007-01-03
MY141992A (en) 2010-08-16
NZ549009A (en) 2010-08-27
AU2005217602A1 (en) 2005-09-09
CR8566A (es) 2006-12-01
DK1720836T3 (da) 2014-05-05
UA85699C2 (en) 2009-02-25
WO2005082859A1 (en) 2005-09-09
EA011011B1 (ru) 2008-12-30
ZA200606580B (en) 2008-02-27
SV2005002025A (es) 2005-11-04
EA200601546A1 (ru) 2007-02-27
DOP2005000024A (es) 2005-11-15
CN102329267A (zh) 2012-01-25
ECSP066788A (es) 2006-11-16
US8580780B2 (en) 2013-11-12
IL177267A0 (en) 2006-12-10
NO20064277L (no) 2006-11-22
US20090099155A1 (en) 2009-04-16
ES2466641T3 (es) 2014-06-10
AR048242A1 (es) 2006-04-12
SI1720836T1 (sl) 2014-06-30
AU2005217602B2 (en) 2011-02-17
EP2479168A1 (en) 2012-07-25
CA2556390C (en) 2012-10-02
JP4796047B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
PE20060010A1 (es) 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPINAS 6-SUSTITUIDAS COMO AGONISTAS DEL RECEPTOR 5-HT2C
PE20010759A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
ES2296763T3 (es) Pirrolidinas disustituidas en 1,3 como amtagonistas de adrenorreceptor alfa-2.
PE20021041A1 (es) DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
PE20090441A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
PE20010681A1 (es) Derivados de benzodiazepina como antagonistas del receptor de glutamato metabotropico
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20021072A1 (es) DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2
PE20091371A1 (es) Inhibidores de hsp90
AR049497A1 (es) Derivados indolicos como moduladores del receptor x del higado; composiciones farmaceuticas y metodos de preparacion
PE20010467A1 (es) 1,2,4,5-tetrahidro-benzo[d]azepin como antagonista del receptor metabotropico de glutamato
PE20061297A1 (es) Compuestos derivados de cromano y cromeno moduladores del receptor de serotonina 5-ht2c
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20001421A1 (es) Sulfonamidas heterociclicas como inhibidores de endotelina
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
PE20081378A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
PE20120593A1 (es) Derivados fusionados de pirimidin-4-ona como antagonistas del receptor de angiotensina ii y como agonistas del receptor ppar gamma
PE20011030A1 (es) Combinaciones farmaceuticas que comprenden tegaserod y omeprazol

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed